Pancreatic Cancer (PC) has a poor prognosis, with a 5-year survival rate of only 9%. Even after radical surgical procedures, PC patients have poor survival rates, with a high chance of relapse (70–80%). Imaging is involved in all aspects of the clinical management of PC, including detection and characterization of primary tumors and their resectability, assessment of vascular, perineural and lymphatic invasion and detection of distant metastases. The role of Positron Emission Tomography/Computed Tomography (PET/CT) in detecting PC is still controversial, with the international guidelines not recommending its routine use. However, in resectable PC, PET/CT may play a role in assessing PC stage and grade and potential resectability after neoadjuvant treatment. Quantitative image analysis (radiomics) and new PET/CT radiotracers account for future developments in metabolic imaging and may further improve the relevance of this technique in several aspects of PC. In the present review, the current state of the art and future directions of PET/CT in resectable PC are presented.

The role of positron emission tomography/computed tomography (Pet/ct) for staging and disease response assessment in localized and locally advanced pancreatic cancer / M. Ghidini, M. Vuozzo, B. Galassi, P. Mapelli, V. Ceccarossi, L. Caccamo, M. Picchio, D. Dondossola. - In: CANCERS. - ISSN 2072-6694. - 13:16(2021 Aug 18), pp. 4155.1-4155.15. [10.3390/cancers13164155]

The role of positron emission tomography/computed tomography (Pet/ct) for staging and disease response assessment in localized and locally advanced pancreatic cancer

M. Ghidini
Primo
;
V. Ceccarossi;D. Dondossola
2021

Abstract

Pancreatic Cancer (PC) has a poor prognosis, with a 5-year survival rate of only 9%. Even after radical surgical procedures, PC patients have poor survival rates, with a high chance of relapse (70–80%). Imaging is involved in all aspects of the clinical management of PC, including detection and characterization of primary tumors and their resectability, assessment of vascular, perineural and lymphatic invasion and detection of distant metastases. The role of Positron Emission Tomography/Computed Tomography (PET/CT) in detecting PC is still controversial, with the international guidelines not recommending its routine use. However, in resectable PC, PET/CT may play a role in assessing PC stage and grade and potential resectability after neoadjuvant treatment. Quantitative image analysis (radiomics) and new PET/CT radiotracers account for future developments in metabolic imaging and may further improve the relevance of this technique in several aspects of PC. In the present review, the current state of the art and future directions of PET/CT in resectable PC are presented.
18; F-FDG; Pancreatic cancer; PET tracers; Positron emission tomography; Radiomics; Resectable disease;
Settore MED/18 - Chirurgia Generale
18-ago-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
cancers-13-04155-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.23 MB
Formato Adobe PDF
1.23 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/919774
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact